BrainScope – point-of-care assessment of brain health

BrainScope has developed a point-of-care platform for the assessment of brain head injuries, including hemorrhages and concussions. The handheld device acquires EEG data from an electrode headset that is then processed by artificial intelligence to measure and determine the extent of head injuries. To-date, BrainScope has raised an estimated $52.1M in capital. The market for solutions to effectively diagnose traumatic brain injuries has recently seen significant activity, with many new startups entering the space in recent years. Other competitors in the traumatic brain injury diagnostics market include Banyan, Medicortex, and NanoDX.

BrainScope is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.

RevBio – a bioresorbable, injectable solution for adhering bone

RevBio’s synthetic biomaterial is a biocompatible bone adhesive that is capable of bonding bone to bone and bone to metal. The company’s patented biomaterial, Tetranite, is being developed as a comprehensive solution for orthoregenerative procedures. RevBio is actively investigating the use of its Tetranite solution in the dental, cranial, fracture repair, and spine fusion markets. In April, the company received a $2M grant from the National Institute on Aging. The funding will allow RevBio to study the use of Tetranite in wrist fractures.

Sense Biodetection raises $50M from Series B round

The molecular diagnostics startup is redefining point-of-care with its simple, cost-effective, handheld molecular diagnostic solution. The company’s Veros platform is intended to be an alternative to lab-constrained polymerase chain reaction (PCR) testing, delivering lab-quality results within minutes with the need for traditional benchtop diagnostic equipment. Sense Biodetection is preparing to launch a COVID-19 POC test on its Veros platform, with additional tests to be added to its portfolio in the future. Other startups that have pursued the development of solutions in response to the COVID-19 pandemic include Cue Health, Luminostics, and Unima.

NIDO is developing an innovative solution for the treatment of ventricular tachycardia

NIDO’s SEPIA solution will allow surgeons to visualize the epicardial surface during ablation procedures for the treatment of ventricular tachycardia. SEPIA will improve the efficiency of ablation procedures, which currently is plagued by technological limitations which result in disease recurrence. The Boston-based startup has raised $2.7M to support the development of their solution. AtriCure and Medtronic are the two of the biggest competitors in the surgical ablation technology market.

NIDO is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.

PyrAmes raises $6M to support commercialization of continuous BP monitoring solutions

The company is currently developing products to enable continuous blood pressure monitoring in pediatrics and adults. PyrAmes lead product, Boppli, is intended for use in the neonatal intensive care unit (NICU) as an alternative to the invasive insertion of an arterial catheter. Boppli is a single-use, wireless sensor band that slips around a baby’s foot or wrist and continuously measures blood pressure. Data is streamed to a bedside device for live monitoring of vital information.